Vanguard Personalized Indexing Management
PCVX icon

Vanguard Personalized Indexing Management’s Vaxcyte PCVX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Sell
25,291
-4,713
-16% -$256K 0.01% 777
2026
Q1 		$1.74M Buy
30,004
+4,780
+19% +$260K 0.02% 661
2025
Q4 		$1.16M Buy
25,224
+9,369
+59% +$419K 0.01% 841
2025
Q3 		$571K Buy
15,855
+3,133
+25% +$104K 0.01% 1187
2025
Q2 		$414K Buy
12,722
+5,753
+83% +$189K ﹤0.01% 1295
2025
Q1 		$263K Buy
6,969
+349
+5% +$27.9K ﹤0.01% 1399
2024
Q4 		$542K Sell
6,620
-96
-1% -$9.53K 0.01% 1075
2024
Q3 		$767K Buy
6,716
+1,866
+38% +$168K 0.01% 900
2024
Q2 		$366K Buy
4,850
+895
+23% +$60.9K 0.01% 1174
2024
Q1 		$270K Buy
3,955
+648
+20% +$44.9K 0.01% 1318
2023
Q4 		$208K Buy
+3,307
New +$172K 0.01% 1401

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Personalized Indexing Management's PCVX Position: Q2 2026 in Review

Vanguard Personalized Indexing Management reduced its Vaxcyte (PCVX) stake by 16% in Q2 2026, selling an estimated $256K and leaving 25,291 shares worth $1.47M. The position accounts for 0.01% of the portfolio, ranked #777.

Vanguard Personalized Indexing Management first reported a position in PCVX in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.74M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Vanguard Personalized Indexing Management held 25,291 shares of Vaxcyte worth $1.47M as of Q2 2026.
  • Vanguard Personalized Indexing Management sold 4,713 Vaxcyte shares in Q2 2026, an estimated $256K.
  • Vaxcyte made up 0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #777 holding.
  • Vanguard Personalized Indexing Management first reported a position in Vaxcyte in Q4 2023 and has held it in 11 quarters since.
  • Vanguard Personalized Indexing Management's Vaxcyte position peaked at $1.74M in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.